UNSPSC 51131754: Taprostene sodium

This classification denotes an antiplatelet agent with the molecular formula C24H29O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M078713KZ, chemically known as benzoic acid, 3-((z)-((3ar,4r,5r,6as)-4-((1e,3s)-3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, monosodium salt, but more generally known as taprostene sodium, which bears US NIH Compound Identifier 6437844.

European Medicines Agency schedules taprostene sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10831MIG. Most nations, for tariff purposes, schedule taprostene sodium under HS 29375000. SMILES: C1CC(CC(C1)C(=O)[O-])/C=C\2/C[C@H]3[C@@H](O2)C[C@H]([C@@H]3/C=C/[C@H](C4CCCCC4)O)O.[NA+].

UNSPSC 51131754 Taprostene sodium is a Commodity code with minimal recent state and local procurement activity. The single identifiable opportunity posted in the source is a Sourcewell cooperative procurement issued as RFP #061626 for Law Enforcement Equipment, posted May 12, 2026 with a response deadline of June 16, 2026 at 3:30 p.m. Central Time. The scope of this solicitation—law enforcement equipment generally—does not align with the nominal code scope (a pharmaceutical product). No state and local solicitations specifically for taprostene sodium or related pharmaceutical procurement appear in the available records.

The Sourcewell RFP is a multi-jurisdictional cooperative vehicle administered by the State of Minnesota on behalf of participating entities across Washington state (Franklin County, Grant County, Grays Harbor County, Chelan County, and Yakima County) and "numerous other jurisdictions and public entities throughout the United States and Canada." The procurement targets state and local government agencies, higher education institutions, school districts, nonprofit organizations, and tribal governments through a framework agreement model. No geographic concentration of pharmaceutical or drug-related state and local procurement under this code is evident from the available opportunities. The absence of aligned solicitations suggests this code either sees infrequent state and local activity or is not the primary classification applied to pharmaceutical procurements by state and local issuing bodies. Vendors evaluating this code should monitor cooperative purchasing vehicles and state health agency solicitations for closer alignment with actual pharmaceutical procurement activity.